Jubilant Ingrevia, a global integrated life science products and innovative solutions provider, is planning to invest Rs. 900 crore in the next three years.

The expected Capex cash outflow for FY22 will be in the range of Rs. 350 crore. In the Speciality Chemicals division, the company is planning an investment to the tune of Rs. 550 crore, Nutrition & Health Solutions division Rs. 100 crore and Life Sciences Chemicals division Rs. 250 crore in the next 3 years.  

In the Speciality Chemicals division, the investment is in the new facility for launching 6 Diketene derivatives and subsequently, adding 8 value-added Diketene derivatives. Investment in GMP and Non-GMP multi product facilities for pharma and crop protection customers and focus on new world class multi-product facilities for pesticides.

Key Investment Plan

• Diketene Capex is as per schedule and will be commissioned during October to December 2021
• CDMO GMP Facility at Bharuch - Expected to be in operation during the quarter April to June 2022
• Two Multi-Purpose plants of Speciality Chemicals - Expected to be in operation during the quarter April to June 2022
• Food Grade Acetic Acid - Expected to be in operation during the quarter April to June 2022
• Acetic Anhydride Plant - Expected to be in operation during the quarter January to March 2023
• Agro Actives Phase-1 - Expected to be in operation during the quarter January to March 2023
• Agro Active plant – Moving up the value chain of crop protection products and growing customer demand
• Niacinamide capacity expansion – Geographic expansion and moving forward for value added end uses
• Nutrition Premix plant – Moving up the value chain from Ingredients to Premixes

Source: Indian Chemical News 

In the Nutrition & Health Solutions division, investment will be to expand Vitamin B3 capacity by around 20% from current 13,000 MT/year and launch various value-added grades of Vitamin B3. Also the facility will be upgraded for US DMF and European CEP compliance and enter the regulated pharma market of Niacinamide and portfolio enhancement with value-added premixes and investment for premix plant expansion.

In the Life Sciences Chemicals division, the company is planning to invest in another Acetic Anhydride facility to increase capacity by around 35% and further strengthen global leadership. Investment is also planned in Green Acetic Acid plant to cater to the bio route Acetyls chain.

At peak capacity these investments are expected to generate additional annual revenue of Rs. 900 crore at prevailing prices.

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

The company offers a broad portfolio of high-quality ingredients that find application in a wide range of industries. The company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.